Tecovirimat is the first-line antiviral treatment recommended for severe mpox or for persons with mpox who are at risk for severe disease; tecovirimat is available in the United States under an expanded access investigational new drug (IND) protocol. During the 2022-2023 mpox outbreak, local U.S. health jurisdictions facilitated access to tecovirimat. In June 2022, Los Angeles County (LAC) rapidly developed strategies for tecovirimat distribution using existing medical countermeasure distribution networks established by the Public Health Emergency Preparedness Program and the Hospital Preparedness Program, creating a hub and spoke distribution network consisting of 44 hub facilities serving 456 satellite sites across LAC. IND patient intake forms were analyzed to describe mpox patients treated with tecovirimat. Tecovirimat treatment data were matched with case surveillance data to calculate time from specimen collection to patients receiving tecovirimat. Among 2,281 patients with mpox in LAC, 735 (32%) received tecovirimat during June 2022-January 2023. Among treated patients, approximately two thirds (508; 69%) received treatment through community clinics and pharmacies. The median interval from specimen collection to treatment was 2 days (IQR = 0-5 days). Local data collection and analysis helped to minimize gaps in treatment access and facilitated network performance monitoring. During public health emergencies, medical countermeasures can be rapidly deployed across a large jurisdiction using existing distribution networks, including clinics and pharmacies.

中文翻译：

---

2022 年 6 月至 2023 年 1 月洛杉矶县 Mpox 爆发高峰期间成功分发 Tecovirimat。


Tecovirimat 是推荐用于严重 MPOX 或有严重疾病风险的 MPOX 患者的一线抗病毒治疗； tecovirimat 可根据扩大使用研究新药 (IND) 协议在美国上市。在 2022-2023 年 MPOX 爆发期间，美国当地卫生管辖区为获得 tecovirimat 提供了便利。 2022 年 6 月，洛杉矶县 (LAC) 利用公共卫生应急准备计划和医院准备计划建立的现有医疗对策分发网络，迅速制定了 tecovirat 分发战略，创建了一个由 44 个中心设施组成的中心辐射分发网络，为 456 人提供服务遍布 LAC 的卫星站点。对 IND 患者入库表进行分析，以描述接受替科维马治疗的 MPOX 患者。将替科维马治疗数据与病例监测数据相匹配，以计算从标本采集到患者接受替科维马的时间。在 LAC 的 2,281 名 MPOX 患者中，735 名（32%）在 2022 年 6 月至 2023 年 1 月期间接受了替考维马。在接受治疗的患者中，约三分之二（508 名；69%）通过社区诊所和药房接受治疗。从标本采集到治疗的中位间隔为 2 天（IQR = 0-5 天）。本地数据收集和分析有助于最大限度地减少治疗获取方面的差距，并促进网络性能监测。在突发公共卫生事件期间，可以利用现有的分销网络（包括诊所和药房）在大范围内快速部署医疗对策。